Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457964 · ClinicalTrials.gov registry record · Phase 1
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00457964 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 36 participants.
The verdict
NCT00457964, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause regression.
Interventions
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457964
The ClinicalTrials.gov registry entry for NCT00457964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 is the first listed.
NCT00457964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00457964 about?
NCT00457964 is a clinical study titled "RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM". The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause ...
What is the current status of trial NCT00457964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2005-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00457964?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00457964?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.